SecBot SecBot

ENLV

Enlivex Ltd.
Nasdaq· Pharmaceutical Preparations· Inc. L3· CIK 0001596812 Biotech & Drug Discovery
$2.70 +0.14 (+5.27%)
Oct 27 4:00 PM ET · prev $2.56
Market cap
$3.5M
Nano cap
Consensus
Buy
86% Buy or better · 7 analysts
Median target
🔒 Subscribers only
Next earnings
Nov 12
in 16 days
1 year
−99.0%
from $259.20 · Oct 28
30 days
−67.2%
from $8.22
52-week range
$2.56–290.40
−99% from high · low Oct 26
Avg volume 20D
158.1K
Oct 8 spike 2.04M
Short interest
🔒 Subscribers only
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
17
analyzed by SecBot
SecBot read BEARISH 9 reports · 90 days
Balance 3 bearish · 2 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 7/9 ·Next Earnings date, Nov 12, 2026
Strongest BEARISH Enlivex announced a cost reduction plan on October 19, 2026, including a ~60% workforce reduction, wind-down…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InstitutionsMIXED

    Q2 2026: 6 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    6 of 7 rate it Buy or better.

  • TrendDOWNTREND

    77% below its 50-day average. New closing low $2.56 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
ARK Investment Management LLCDOUBLED2,382,731$1.3M
BANK OF AMERICA CORP /DE/ADD193,150$106.0K
SUSQUEHANNA INTERNATIONAL GROUP, LLPDOUBLED157,648$86.7K
GEODE CAPITAL MANAGEMENT, LLCADD129,858$71.4K
SIMPLEX TRADING, LLCDOUBLED111,406$61.3K
UBS Group AGTRIM73,909$40.6K
MORGAN STANLEYNEAR_EXIT8,497$4.7K
GROUP ONE TRADING LLCDOUBLED1,042$573.00

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Buy 86% rate it Buy or better
Strong Buy2Buy4Hold1Sell0Strong Sell0

Fresh Price Targets

Analyst price targets updated within the last 24 hours are for subscribers only.

Subscribe for Full Access
Recent actions
DateFirmActionRating
Aug 3, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Earnings setup

Estimates
Nov 12
reports in 16 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 12, 2026
Earnings date
ENLV Q3 2026 Earnings Scheduled — 2026-11-12
Recent
Oct 27, 2026
Trading halt
🔒 Fresh data, subscribers only
Oct 26, 2026
Trading halt
🔒 Fresh data, subscribers only
Oct 22, 2026
Announcement
Enlivex Announces 1-for-16 Reverse Share Split to be Effective October 27, 2026
Nes-Ziona, Israel, Oct. 22, 2026 (GLOBE NEWSWIRE) -- Enlivex Ltd. (Nasdaq: ENLV) (
Oct 19, 2026
FDA
Enlivex Announces Cost Reduction Plan to Focus Resources on Phase 2b Trial of Allocetra™ in Age-Related Primary Moderate-to-Severe Knee Osteoarthritis
Non-clinical R&D activities to be wound down; resources to be focused on executing the Phase 2b trialWorkforce reduced by approximately 60%…
Aug 27, 2026
Earnings date
ENLV Q2 2026 Earnings Scheduled — 2026-08-27

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Trading halts
Oct 26, 2026🔒 Fresh data, subscribers only
Jul 8, 2026Resumption ScheduledResumed
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 27, 2026 Trading halt
🔒 Fresh data, subscribers only
Oct 27, 2026 SEC
🔒 Fresh report (last 24h), subscribers only
Oct 22, 2026 SEC
Enlivex Ltd. announced a 1-for-16 reverse share split effective October 27, 2026, approved by shareholders at an…
6-K — Impact 3/10
Oct 22, 2026 Press
Enlivex announced a 1-for-16 reverse stock split effective October 27, 2026, to regain compliance with Nasdaq listing…
Impact 3/10
Oct 19, 2026 SEC
Enlivex announced a cost reduction plan on October 19, 2026, including a ~60% workforce reduction, wind-down of…
6-K — Impact 6/10
Oct 19, 2026 Press
Enlivex announced a cost reduction plan to wind down non-clinical R&D, cut workforce by ~60%, and reduce…
Impact 6/10
Jun 30, 2026 Inst.
ARK Investment Management LLC — DOUBLED
2,382,731 shares ($1.3M)
Jun 30, 2026 Inst.
BANK OF AMERICA CORP — ADD
193,150 shares ($106.0K)

SecBot reports

17 filings · 5 press releases · 6 bullish · 4 bearish · 7 neutral
All ENLV filing & press-release reports (22)